SUTENT (sunitinib) for Gastrointestinal Stromal Tumor, Renal Cell Carcinoma & Pancreatic Neuroendocrine Tumors - Cancer Therapy Advisor

SUTENT (sunitinib) for Gastrointestinal Stromal Tumor, Renal Cell Carcinoma & Pancreatic Neuroendocrine Tumors

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for SUTENT (sunitinib), indicated for gastrointestinal stromal tumor, advanced renal cell carcinoma & advanced pancreatic neuroendocrine tumors.
Table of Contents
Slide 3: Indication, Dosage, and Administration
Slide 7: Use in Specific Populations
Slide 9: Clinical Pharmacology
Slide 13: Warnings and Precautions
Slide 18: Clinical Safety and Efficacy
Slide 34: Drug Storage and Supply
Slide 36: References

Next hm-slideshow in Slides